TGF-β signaling pathway as a pharmacological target in liver diseases

Akhurst, 2012, Targeting the TGFbeta signalling pathway in disease, Nat Rev Drug Discov, 11, 790, 10.1038/nrd3810 Dooley, 2012, TGF-beta in progression of liver disease, Cell Tissue Res, 347, 245, 10.1007/s00441-011-1246-y Roberts, 1981, New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues, Proc Natl Acad Sci U S A, 78, 5339, 10.1073/pnas.78.9.5339 Galat, 2011, Common structural traits for cystine knot domain of the TGFbeta superfamily of proteins and three-fingered ectodomain of their cellular receptors, Cell Mol Life Sci, 68, 3437, 10.1007/s00018-011-0643-4 Shi, 2011, Latent TGF-beta structure and activation, Nature, 474, 343, 10.1038/nature10152 Liu, 2010, Regulation of TGF-beta signalling by protein phosphatases, Biochem J, 430, 191, 10.1042/BJ20100427 Gatza, 2010, Roles for the type III TGF-beta receptor in human cancer, Cell Signal, 22, 1163, 10.1016/j.cellsig.2010.01.016 Kang, 2009, New regulatory mechanisms of TGF-beta receptor function, Trends Cell Biol, 19, 385, 10.1016/j.tcb.2009.05.008 Zi, 2012, Dynamics of TGF-beta/Smad signaling, FEBS Lett, 586, 1921, 10.1016/j.febslet.2012.03.063 Xu, 2012, Post-translational regulation of TGF-beta receptor and Smad signaling, FEBS Lett, 586, 1871, 10.1016/j.febslet.2012.05.010 Javelaud, 2005, Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis, Oncogene, 24, 5742, 10.1038/sj.onc.1208928 Landstrom, 2010, The TAK1-TRAF6 signalling pathway, Int J Biochem Cell Biol, 42, 585, 10.1016/j.biocel.2009.12.023 Margadant, 2010, Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing, EMBO Rep, 11, 97, 10.1038/embor.2009.276 Remy, 2004, PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3, Nat Cell Biol, 6, 358, 10.1038/ncb1113 Minoo, 2010, Cross-talk between transforming growth factor-beta and Wingless/Int pathways in lung development and disease, Int J Biochem Cell Biol, 42, 809, 10.1016/j.biocel.2010.02.011 Guo, 2009, Signaling cross-talk between TGF-beta/BMP and other pathways, Cell Res, 19, 71, 10.1038/cr.2008.302 Zhang, 2009, Non-Smad pathways in TGF-beta signaling, Cell Res, 19, 128, 10.1038/cr.2008.328 Mu, 2012, Non-Smad signaling pathways, Cell Tissue Res, 347, 11, 10.1007/s00441-011-1201-y Matsuzaki, 2011, Smad phosphoisoform signaling specificity: the right place at the right time, Carcinogenesis, 32, 1578, 10.1093/carcin/bgr172 Murata, 2009, Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B, Hepatology, 49, 1203, 10.1002/hep.22765 Hong, 2012, Transforming growth factor-beta1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4alpha expression, PLOS ONE, 7, e30360, 10.1371/journal.pone.0030360 Park, 2012, TGF-beta and iron differently alter HBV replication in human hepatocytes through TGF-beta/BMP signaling and cellular microRNA expression, PLOS ONE, 7, e39276, 10.1371/journal.pone.0039276 Bruha, 2012, Alcoholic liver disease, World J Hepatol, 4, 81, 10.4254/wjh.v4.i3.81 Gerjevic, 2012, Alcohol activates TGF-beta but inhibits BMP receptor-mediated Smad signaling and Smad4 binding to hepcidin promoter in the liver, Int J Hepatol, 2012, 459278, 10.1155/2012/459278 Ciuclan, 2010, TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I, J Hepatol, 52, 407, 10.1016/j.jhep.2009.12.003 Choi, 2009, Epithelial-to-mesenchymal transitions in the liver, Hepatology, 50, 2007, 10.1002/hep.23196 Das, 2011, Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease, Indian J Clin Biochem, 26, 202, 10.1007/s12291-011-0121-7 Braunersreuther, 2012, Role of cytokines and chemokines in non-alcoholic fatty liver disease, World J Gastroenterol, 18, 727, 10.3748/wjg.v18.i8.727 Yndestad, 2009, A complex role of activin A in non-alcoholic fatty liver disease, Am J Gastroenterol, 104, 2196, 10.1038/ajg.2009.318 Rodgarkia-Dara, 2006, The activin axis in liver biology and disease, Mutat Res, 613, 123, 10.1016/j.mrrev.2006.07.002 Yndestad, 2011, Activin A in nonalcoholic fatty liver disease, Vitam Horm, 85, 323, 10.1016/B978-0-12-385961-7.00015-9 Lee, 2011, Mechanisms of hepatic fibrogenesis, Best Pract Res Clin Gastroenterol, 25, 195, 10.1016/j.bpg.2011.02.005 Dobaczewski, 2010, Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction, Circ Res, 107, 418, 10.1161/CIRCRESAHA.109.216101 Biernacka, 2011, TGF-beta signaling in fibrosis, Growth Factors, 29, 196, 10.3109/08977194.2011.595714 Dooley, 2009, Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma, Dig Dis, 27, 93, 10.1159/000218340 Mu, 2013, TGF-beta signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells, PLOS ONE, 8, e63436, 10.1371/journal.pone.0063436 Jirtle, 1991, Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression, Dig Dis Sci, 36, 659, 10.1007/BF01297035 Fransvea, 2009, Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma, Hepatology, 49, 839, 10.1002/hep.22731 Van Zijl, 2009, Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge, Oncogene, 28, 4022, 10.1038/onc.2009.253 Reichl, 2012, TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma, Curr Pharm Des, 18, 4135, 10.2174/138161212802430477 Jaschinski, 2011, The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2, Curr Pharm Biotechnol, 12, 2203, 10.2174/138920111798808266 Giannelli, 2011, Inhibiting TGF-beta signaling in hepatocellular carcinoma, Biochim Biophys Acta, 1815, 214 Mead, 2003, Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery, Invest Ophthalmol Vis Sci, 44, 3394, 10.1167/iovs.02-0978 Denton, 2007, Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192, Arthritis Rheum, 56, 323, 10.1002/art.22289 Stevenson, 2013, Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients, Oncoimmunology, 2, e26218, 10.4161/onci.26218 Dituri, 2013, Differential inhibition of the TGF-beta signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-beta receptor type II, PLOS ONE, 8, e67109, 10.1371/journal.pone.0067109 Yang, 2002, Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects, J Clin Invest, 109, 1607, 10.1172/JCI200215333 Bandyopadhyay, 2002, Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells, Oncogene, 21, 3541, 10.1038/sj.onc.1205439 Ezquerro, 2003, A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury, Cytokine, 22, 12, 10.1016/S1043-4666(03)00101-7 Santiago, 2005, Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis, J Invest Dermatol, 125, 450, 10.1111/j.0022-202X.2005.23859.x Inman, 2002, SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, Mol Pharmacol, 62, 65, 10.1124/mol.62.1.65 Sawyer, 2004, Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain, Bioorg Med Chem Lett, 14, 3581, 10.1016/j.bmcl.2004.04.007 Li, 2008, Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent, J Med Chem, 51, 2302, 10.1021/jm701199p Fransvea, 2008, Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells, Hepatology, 47, 1557, 10.1002/hep.22201 Nakao, 1997, Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling, Nature, 389, 631, 10.1038/39369 Iglesias, 2000, Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas, Oncogene, 19, 4134, 10.1038/sj.onc.1203764 Kleeff, 1999, The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer, Oncogene, 18, 5363, 10.1038/sj.onc.1202909